BACKGROUND: Leukemia is the leading cause of disease-related death in children, despite significant improvement in survival and modern risk stratification. The prognostic significance of absolute lymphocyte counts (ALC) was evaluated in young patients with acute myeloblastic leukemia (AML) and acute lymphoblastic leukemia (ALL). METHODS: In all, 171 consecutive de novo cases of AML and ALL, age <or=21 years, were analyzed. Age, initial white blood cell count, cytogenetics, and bone marrow response were compared with lymphocyte, neutrophil, and platelet counts at weekly intervals during induction chemotherapy. RESULTS: ALC is a significant independent predictor of relapse and survival. For example, in patients with AML an ALC on Day 28 of induction (ALC-28) <350 cells/microL predicts very poor survival, with a 5-year relapse-free survival (RFS) of only 10% (hazard ratio [HR] 3.7, P= .003). In contrast, an ALC-15 >350 cells/microL carries an excellent prognosis, with a 5-year overall survival (OS) of 85% (HR 0.2, P= .012). Similarly in ALL, an ALC-15 <350 cells/microL predicts poor survival, with a 6-year RFS of 43% (HR 4.5, P= .002), whereas an ALC-15 >350 cells/microL predicts excellent outcome, with a 6-year OS of 87% (HR 0.2, P= .018). Importantly, ALC remains a strong predictor in multivariate analysis with known prognostic factors. CONCLUSIONS: ALC is a simple, statistically powerful measurement for patients with de novo AML and ALL. The results, when combined with previous studies, demonstrate that ALC is a powerful new prognostic factor for a range of malignancies. These findings suggest a need for further exploration of postchemotherapy immune status and immune-modulating cancer therapies.
BACKGROUND:Leukemia is the leading cause of disease-related death in children, despite significant improvement in survival and modern risk stratification. The prognostic significance of absolute lymphocyte counts (ALC) was evaluated in young patients with acute myeloblastic leukemia (AML) and acute lymphoblastic leukemia (ALL). METHODS: In all, 171 consecutive de novo cases of AML and ALL, age <or=21 years, were analyzed. Age, initial white blood cell count, cytogenetics, and bone marrow response were compared with lymphocyte, neutrophil, and platelet counts at weekly intervals during induction chemotherapy. RESULTS: ALC is a significant independent predictor of relapse and survival. For example, in patients with AML an ALC on Day 28 of induction (ALC-28) <350 cells/microL predicts very poor survival, with a 5-year relapse-free survival (RFS) of only 10% (hazard ratio [HR] 3.7, P= .003). In contrast, an ALC-15 >350 cells/microL carries an excellent prognosis, with a 5-year overall survival (OS) of 85% (HR 0.2, P= .012). Similarly in ALL, an ALC-15 <350 cells/microL predicts poor survival, with a 6-year RFS of 43% (HR 4.5, P= .002), whereas an ALC-15 >350 cells/microL predicts excellent outcome, with a 6-year OS of 87% (HR 0.2, P= .018). Importantly, ALC remains a strong predictor in multivariate analysis with known prognostic factors. CONCLUSIONS: ALC is a simple, statistically powerful measurement for patients with de novo AML and ALL. The results, when combined with previous studies, demonstrate that ALC is a powerful new prognostic factor for a range of malignancies. These findings suggest a need for further exploration of postchemotherapy immune status and immune-modulating cancer therapies.
Authors: L Katie Crosley; Susan J Duthie; Abigael C Polley; Freek G Bouwman; Carolin Heim; Francis Mulholland; Graham Horgan; Ian T Johnson; Edwin C Mariman; Ruan M Elliott; Hannelore Daniel; Baukje de Roos Journal: Genes Nutr Date: 2009-04-29 Impact factor: 5.523
Authors: Stuart A Grossman; Xiaobu Ye; Glenn Lesser; Andrew Sloan; Hetty Carraway; Serena Desideri; Steven Piantadosi Journal: Clin Cancer Res Date: 2011-07-07 Impact factor: 12.531
Authors: Lutz Zeidler; Martin Zimmermann; Anja Möricke; Barbara Meissner; Dorothee Bartels; Christoph Tschan; André Schrauder; Gunnar Cario; Lilia Goudeva; Sarah Jäger; Richard Ratei; Wolf-Dieter Ludwig; Andrea Teigler-Schlegel; Julia Skokowa; Rolf Koehler; Claus R Bartram; Hansjörg Riehm; Martin Schrappe; Karl Welte; Martin Stanulla Journal: Haematologica Date: 2011-11-04 Impact factor: 9.941
Authors: Karen R Rabin; M Monica Gramatges; Michael J Borowitz; Shana L Palla; Xiaodong Shi; Judith F Margolin; Patrick A Zweidler-McKay Journal: Pediatr Blood Cancer Date: 2011-11-18 Impact factor: 3.167
Authors: Jeffrey E Rubnitz; Patrick Campbell; Yinmei Zhou; John T Sandlund; Sima Jeha; Raul C Ribeiro; Hiroto Inaba; Deepa Bhojwani; Mary V Relling; Scott C Howard; Dario Campana; Ching-Hon Pui Journal: Cancer Date: 2013-03-01 Impact factor: 6.860